Photo of Whitt Steineker

As co-chair of Bradley’s Cannabis Industry team, Whitt represents clients in a wide range of cannabis issues. In addition to providing a full suite of legal services to cannabis companies, Whitt and the Cannabis Industry team advise non-cannabis clients – from banks to commercial real estate companies to insurance companies and high net worth individuals – on best practices for interacting with cannabis companies.

Whitt is one of the leading voices in the cannabis bar – recognized as a “Go-To Thought Leader” by the National Law Review. He has presented on cannabis issues at conferences around the country.  His work has been featured in the National Law JournalLaw360, and the Westlaw Journal. And he has been quoted in an array of legal and mainstream publications from Law360 and Super Lawyers to the Atlanta Journal-Constitution and the Associated Press.

In The Usual Suspects, Verbal Kint explains the final reveal of the film, and I stress the world “film”: “The greatest trick the devil ever pulled was convincing the world he didn’t exist.” I thought about that line while reading the latest from Washington on hemp because the looming federal change to hemp THC

President Trump has announced he will nominate Todd Blanche — his former personal attorney, who has been running the Department of Justice in an acting capacity — to serve as permanent attorney general. I wrote back in April about the personnel shuffle that put Blanche in the acting AG chair and what it might mean

It’s déjà vu all over again. In a move that surprised many — and disappointed more — Virginia Gov. Abigail Spanberger has vetoed legislation that would have finally established a regulated adult-use marijuana retail market in the Commonwealth. The veto is notable not just for what it means for Virginia consumers and operators, but for

Good news for people who don’t want their airline pilots any higher than they already are.

If you’ve been following the rescheduling saga as closely as I have, you might have assumed that once President Trump signed the executive order directing DEA to move state-licensed medical marijuana and DEA-approved medications to Schedule III, the ripple

We are going to white knuckle our way through a blog post about lawyers and guns without doing the obligatory Warren Zevon plug, but we want you to understand how hard this is for us.

Loyal readers of Budding Trends are well aware of marijuana rescheduling, but we offer the following for those who may

In the summer of 2017, Phish lit up Madison Square Garden with a historic 13-night run. Your friends at Budding Trends believe the marijuana rescheduling decision calls for a rollout just as monumental, so we’ve created the Budding Trends Baker’s Dozen as a fitting homage.

Following the federal government’s move to reschedule medical marijuana from

One of the questions I have been asked most often since the Acting Attorney General Todd Blanche signed a final order moving FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act is whether the federal government’s decision to move state-licensed medical marijuana to Schedule III will

If you’re familiar with operators in the marijuana industry in the United States, you understand that they can be a paranoid bunch — and often with very good reasons. After all, they operated in the grayest areas of the law for years. I can’t help but think of one of the great anthems of the

Dr. Marty Makary resigned as FDA commissioner last week, barely a year after his Senate confirmation. HHS Secretary Robert F. Kennedy Jr. confirmed the departure and indicated the agency is searching for a replacement. Kyle Diamantas, FDA’s deputy commissioner for Food, will serve as acting commissioner in the meantime. The vacancy arrives at an extraordinarily

“What a long, strange trip it’s been.”

When we launched Budding Trends years ago as a modest little blog focused on cannabis law, the idea that we’d one day spend serious time tracking potential widespread access to psychedelics was, to put it mildly, not part of the original pitch deck. And yet, here we are.